Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
Samo za registrovane korisnike
2011
Autori
Antić, DarkoMihaljević, Biljana
Čokić, Vladan
Dencic-Fekete, Marija
Karan-Đurašević, Teodora
Pavlović, Sonja
Milić, Nataša
Elezović, Ivo
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).
Ključne reči:
Lymphoma and Hodgkin disease / molecular genetics / prognosticationIzvor:
Leukemia & Lymphoma, 2011, 52, 7, 1394-1397Izdavač:
- Taylor & Francis Ltd, Abingdon
DOI: 10.3109/10428194.2011.578311
ISSN: 1042-8194
PubMed: 21699385
WoS: 000291992400036
Scopus: 2-s2.0-79959613190
Institucija/grupa
Institut za medicinska istraživanjaTY - JOUR AU - Antić, Darko AU - Mihaljević, Biljana AU - Čokić, Vladan AU - Dencic-Fekete, Marija AU - Karan-Đurašević, Teodora AU - Pavlović, Sonja AU - Milić, Nataša AU - Elezović, Ivo PY - 2011 UR - http://rimi.imi.bg.ac.rs/handle/123456789/336 AB - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001). PB - Taylor & Francis Ltd, Abingdon T2 - Leukemia & Lymphoma T1 - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling EP - 1397 IS - 7 SP - 1394 VL - 52 DO - 10.3109/10428194.2011.578311 ER -
@article{ author = "Antić, Darko and Mihaljević, Biljana and Čokić, Vladan and Dencic-Fekete, Marija and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo", year = "2011", abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).", publisher = "Taylor & Francis Ltd, Abingdon", journal = "Leukemia & Lymphoma", title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling", pages = "1397-1394", number = "7", volume = "52", doi = "10.3109/10428194.2011.578311" }
Antić, D., Mihaljević, B., Čokić, V., Dencic-Fekete, M., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397. https://doi.org/10.3109/10428194.2011.578311
Antić D, Mihaljević B, Čokić V, Dencic-Fekete M, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397. doi:10.3109/10428194.2011.578311 .
Antić, Darko, Mihaljević, Biljana, Čokić, Vladan, Dencic-Fekete, Marija, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397, https://doi.org/10.3109/10428194.2011.578311 . .